基于SCP分析的我国医药制造业市场绩效实证研究

发布时间：2018-02-01 08:34

本文关键词： 医药制造业市场绩效实证分析　出处：《山东中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：医药制造业是关乎国计民生的重要产业,随着2009年医药卫生体制改革的进行,近年来我国医药制造业获得了迅猛的发展势头,同时随着我国人口数量的增长、全面放开二孩政策的实施,以及人口老龄化的增长、人们对健康意识的增强,我国的医药制造业获得了强大并持久的需求量。而当前,我国医药制造业面临研发投入强度较低、产业集中度影响规模经济等问题,一定程度上制约了我国医药市场的供给量。为了对我国当前的医药制造业有一个较清晰客观的认识,发现其近年来的发展规律,本文采用了中观研究领域的产业组织理论即SCP分析范式,对我国医药制造业的市场结构和市场行为展开了细致、全面的分析,主要涉及到产业集中度、产品差异化、进入退出壁垒、研发强度及并购行为等,发现我国医药制造业目前的发展状态是喜中有忧,总体呈现出蒸蒸日上的发展势头,但是仍存在很多的问题亟需政府、企业等力量的贡献。在此基础上,本文引入了研究产业市场绩效的常用方法—主成分分析法,通过国家统计局网站获取《中国统计年鉴》中的相关指标数据,选取了11个规整后的经济指标,结合2006—2014年这9年的数据,展开了实证模型分析,最后发现近九年来我国医药制造业总体越发向好,但其增长速度相对来说是不同的,2007年、2008年绩效相对降低,应该与当时全球金融危机的影响有关,2011年、2012年发展势头尤其迅猛,与2009年后实施的医药卫生体制改革等密不可分,之后的2013年、2014年增长速度开始放缓,这需要我们政府部门等相关方的重视。
[Abstract]:Pharmaceutical manufacturing industry is an important industry related to the national economy and people's livelihood. With the reform of the medical and health system in 2009, the pharmaceutical manufacturing industry in China has gained a rapid development momentum in recent years. At the same time, with the increase of population, the implementation of the policy of opening up the two-child policy, and the aging of the population, people's awareness of health has been strengthened. The pharmaceutical manufacturing industry in our country has got a strong and lasting demand. At present, the pharmaceutical manufacturing industry in our country is faced with the problems of low R & D investment intensity and the influence of industrial concentration on economies of scale and so on. In order to have a clear and objective understanding of the current pharmaceutical manufacturing industry in our country, we find out its development law in recent years. In this paper, the industrial organization theory in the field of mesoscopic research, or SCP analysis paradigm, is used to analyze the market structure and market behavior of Chinese pharmaceutical manufacturing industry in detail and comprehensively, mainly involving the degree of industrial concentration. Product differentiation, entry and exit barriers, R & D intensity and M & A behavior, found that the current state of development of the pharmaceutical manufacturing industry in China is mixed, overall showing a growing momentum of development. However, there are still many problems in need of government, enterprises and other forces to contribute. On this basis, this paper introduces a common method to study industrial market performance-principal component analysis. Through the National Bureau of Statistics website to obtain the relevant indicators in the "China Statistical Yearbook" data, selected 11 regular economic indicators, combined with the 2006-2014 data for the nine years. The empirical model analysis is carried out, and it is found that in the last nine years, the overall growth rate of pharmaceutical manufacturing industry in China is more and more positive, but its growth rate is relatively different. In 2007 and 2008, the performance of pharmaceutical manufacturing industry is relatively lower. It should be related to the impact of the global financial crisis at that time. The momentum of development was particularly rapid in 2011 and 2012. It was closely related to the reform of the medical and health system implemented after 2009. In 2014, the rate of growth began to slow, which requires the attention of our government departments and other relevant parties.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：F426.72

【相似文献】